ArticleJournal of the National Cancer Center2022
Lung cancer incidence and mortality in China: Updated statistics and an overview of temporal trends from 2000 to 2016.
Article in Journal of the National Cancer Center, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single-Arm Study.Thoracic cancer · 2025Trial
- Epidemiological characteristics and risk factors of lung cancer in a population with incidental pulmonary nodules in China: a prospective multicenter study of 10,560 cases.Journal of the National Cancer Center · 2026Article
- Integrative analysis and experimental validation of dioxin-interacting genes reveal diagnostic and prognostic biomarkers in lung adenocarcinoma.Clinical and experimental medicine · 2026Article
- Lung cancer mortality trends in China from 2013 to 2021 and projections to 2030.Cancer biology & medicine · 2026Article
- Moderated mediating effects of perceived loneliness and economic burden between social support and mental health for lung cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development.Anti-cancer drugs · 2026Article
- Patient profiles, incidence and trends of lung cancer in Ethiopia from 2012 to 2023 using a cancer registry.Scientific reports · 2026Article
- The function of phosphoglycerate mutase 1 (PGAM1) and its role in diseases.Frontiers in molecular biosciences · 2026Review
- Serum tumor markers combined with HRCT for malignancy risk assessment of solitary pulmonary nodules: a retrospective study.Frontiers in genetics · 2026Article
- Construction of a postoperative home-based pulmonary rehabilitation program protocol for lung cancer patients delivered using the internet: A Delphi-based study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- The Clinical Characteristics, Treatment, and Prognosis of Lung Cancer in Young Patients in the New Era of Cancer Treatment: A Retrospective and Comprehensive Analysis.Current oncology (Toronto, Ont.) · 2025Article
- Prevalence and associated factors of cognitive frailty in older patients with lung cancer undergoing chemotherapy: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Cancer mortality trends in China from 2013-2021 and projections to 2030.Cancer biology & medicine · 2025Article
- Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study.BMC cancer · 2025Article
- miR-17-5p is highly expressed in patients with lung cancer and promoted lung cancer by targeting SIK1.Discover oncology · 2025Article
- First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation-positive non-small cell lung cancer: protocol for a multicenter, prospective, observational study.Frontiers in oncology · 2025Article
- Impact of duration of maintenance immunotherapy on the prognosis of locally advanced non-small cell lung cancer treated with chemoradiotherapy.Frontiers in oncology · 2025Article
- Comprehensive analysis of RFC4 as a potential biomarker for regulating the immune microenvironment and predicting immune therapy response in lung adenocarcinoma.Frontiers in immunology · 2025Article
- The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer.Frontiers in public health · 2025Article
- SEC61G Facilitates Brain Metastases via Antagonizing PGAM1 Ubiquitination and Immune Microenvironment Remodeling in Non-Small Cell Lung Cancer.International journal of biological sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Updated systematic statistics on lung cancer are the underpinning cornerstones for formulating prevention and control strategies for the disease. The incidence and mortality data of lung cancer in China in 2016 were estimated, and also used to analyze the temporal trends of lung cancer from 2000 up to 2016 in this study. Methods: The burden of lung cancer in China in 2016 was estimated using data from 487 cancer registries, which were abstracted from the database of the National Cancer Center of China (NCC). The temporal trends were estimated with the data of 2000 to 2016 from 22 cancer registries. Results: About 828,100 new lung cancer cases and 657,000 lung cancer deaths were estimated in China in 2016. The crude incidence and mortality rates in the eastern region were the highest nationwide. The incidence and mortality of lung cancer increased with age, and most of the new cases occurred in the age group of over 60 years. The age-standardized incidence increased by about 0.8% per year during 2000 to 2016, especially in woman, whose annual increase rate reached 2.1%. The age-standardized mortality rate decreased by about 0.6% per year, with a decrease of 1.3% per year in urban areas and an increase of 2.3% per year in rural areas. The numbers of new cases and deaths increased by 162.6% and 123.6%, respectively, during 2000 to 2016, which can be explained mainly by the change of the age structure. Conclusions: The burden of lung cancer is serious in China, and increased especially rapidly for women in rural areas. The disease is expected to threaten the lives of more people in the future due to factors such as aging and population growth. Lung cancer prevention and control strategies and resources should be leveraged toward women and rural areas in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.